Todos Med Ltd (TOMDF)

[JoeForkeyBolo]

werd, your posts suggest you believe Pfizer understands the molecular target of the 3CL protease enzyme better than Todos. Fact is, Todos partnered with NLC Pharma, which probably has as much experience and research with the 3C and 3CL protease enzymes as does Pfizer. It is my belief they are at least on even footing, and perhaps the NLC Pharma joint venture gives Todos the advantage over Pfizer, since the Tollovir product has also been shown to suppress the cytokine storm that is a dangerous immune system response.

I do agree with you, however, that a buyout offer may be at least a possibility, but probably after trial results are published (but then at a much higher price if results are good).